Since insulin is a crucial regulator of SREBP-1c, improvements in insulin sensitivity, potentially facilitated by probiotics, could inhibit fatty acid synthesis, offering additional protection against hepatic steatosis (104, 106). This evidence concerns the gene INS and fatty liver disease.